Comparison of Time to Clinically Meaningful Improvement in Neuro-QOL in Patients Treated with Natalizumab Versus Ocrelizumab
1Carrie M. Hersh, 2Carl De Moor, 3Deborah M. Miller, 2Robin Avila, 2James R. Williams, 4Kathryn C. Fitzgerald, 2Menglan Pang, 3Marisa P. Mcginley, 5Megan Hyland, 6Tjalf Ziemssen, 7Irene Koulinska 1Mellen Program for MS, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, United States; 2Biogen, Cambridge, United States; 3Mellen Center, Cleveland Clinic, Cleveland, United States;…